Well after all the earlier promises, now slightly overdue and the SMA chart starting to indicate a reversal of fortune I think you might be wise to buy some. Or if you hold some, top up as I've been doing lately.

For those not familiar with this stock check on previous news over the last year or so re 'promises'.

soul also PLE have many products about 11 now I think -I have the company report and everytime I read it I feel more assured and confident.
Apparently the deal was delayed because the two companies they were in negotiations with merged and now the merger has happened the negotiations have advanced again. The main point of the mega deal (will happen going by the company's RNS this month/next as they state significant licensing revenue for second half 2006) is that PE market is 25-30% whereas ED is 10% so you can see how big the deal will be!!
The target 526 will be the start of things imho with other deals I see at least 10 -may sound daft now but in a year or so I feel its achievable .
Their top scientist has 80 patents in his name including Viagra which he was part of. All other managment peeps are top guys -best Pharma company for me in a longwhile! glad to have bought at these levels a bargain -even better than Matalan sales!!

overhang cleared at last!! come on baby!

Hondaman, thanks very much for the informative update and your views. I have long been convinced that this company should get a significant re-rating; how long I will hold is another thing as I know that products can take a long time to get to market and I may prefer to get out early rather than sit through a lot more quiet patches.

Just seen the SP, and am delighted to report that my purchase has broken even :o)

PLE Bid: 195p Offer: 202p Change: 6.5

I had not been aware of a stock overhang but it makes sense given the shape of the chart this year.

Nice to see that the spread has narrowed a bit too.

FWIW there has been a nice 50-point rise on the FTSE so far today, which must be helping sentiment.

soul -do us a favour -any other shares that you think will do well at anytime please let me know on this board if its ok by you.

HM, have you seen Renesola (SOLA)? Results due out in two days' time, and they ought to be a real cracker. It's already profitable, expanding rapidly, may be a bit risky as it is in China but has chosen to list on AIM. huge amount of potential cash generation, though. Best place for the reports and articles is FT.com (you may want to print stuff out as they don't seem to make it available for very long). It's worth having a read of the thread on this BB too (and over the road if you have a lot of time on your hands!)

Tipped by two analysts so far, each with target price of 300p; could easily be 5 - 8 between end of 2007 and mid-2008 or by the 2008 FY results.

I got in initially at 145p and increased about ten days ago at just under 200p. You could say it's may favourite stock at the mo.

PDYOR, etc.

thanks soul I'll have a look. keep em coming!

soul I actually saw SOLA a while back except I didn't jump in early enough and then saw it again below 2 and missed the chance again!!!
thats why I could do with tips before they move up so look forward to your other tips as you seem to jump in at the right time! well done!
anyways Plethora overhang has definately cleared hence the move up today so far again with a few buys which confirms that!

Honda, I don't get all my timing right - it's a case of not always having the csh to invest when I want to, plus of course we all make errors of judgment.

I do read a lot of different threads on here though, as well as doing a fair bit of research into the co's behind them.

Another nice bit of progress today though: PLE Bid: 200p Offer: 208p Change: 4

some more info showing confidence Plethora have signed a deal with Inyx to manufacture the aerosol for PSD502 for phase III trials.

So they did:

Inyx Signs Deal with Plethora Solutions to Produce Novel HFA Aerosol Indicated for the Treatment of Premature Ejaculation for Clinical Trial in the United States




NEW YORK, Nov. 2 /PRNewswire-FirstCall/ -- Inyx, Inc. , a specialty pharmaceutical company focused on niche drug delivery technologies and products, announced today that it has signed an agreement with Plethora Solutions Holdings plc (AIM: PLE), an emerging U.K. specialty pharmaceutical company, to manufacture a topical HFA aerosol product used in the treatment of premature ejaculation (PE) for Phase III clinical trial in the United States. The production will be conducted at Inyx USA's FDA-approved site in Puerto Rico.

Jack Kachkar, M.D., Chairman and CEO of Inyx, Inc., said, "We are very pleased that Inyx has been selected for the production of Plethora's PE product for the Phase III clinical trial. We are particularly delighted that a U.K.-based company has selected Inyx USA. This collaboration reflects our expertise in HFA aerosol production and our overall capabilities on both sides of the Atlantic."

Dr. Steven Powell, CEO of Plethora, commented, "We are very happy with our collaboration with Inyx, which allows us to progress PSD502 down the path towards Phase III clinical development."

Plethora's PE product, known as PSD502, is a topical agent comprised of a unique proprietary and rapidly absorbed formulation of two well established local anesthetics, dispensed by a metered dose spray.

PE is a medically recognized condition defined as "persistent or recurrent ejaculation with minimal sexual stimulation before, upon or shortly after penetration, and before the person wishes it." PE is the most common form of sexual dysfunction in men. According to the American Medical Association, approximately 20 million men in the U.S. experience PE. Since there is currently no approved pharmaceutical therapy, the PE market offers significant potential for development and growth. An effective drug therapy for PE may have a commercial potential comparable to the erectile dysfunction drug, Viagra(R), for which current annual sales are approximately $1.7 billion.



Source: http://www.wivb.com/Global/story.asp?S=5625837

or just Google it.

Good find, Hondaman, thanks very much!

some more info showing confidence Plethora have signed a deal with Inyx for them to manufacture the aerosol for PSD502 for phase III trials for Plethora.
(http://www.inyxinc.com/page420618.aspx)

Just my feeling but I am going for a deal to be announced this month.
Lets see -good luck all!! although we have been informed by RNS that it will be in second half so not long to go anyways!

from recent results -this is the interesting part for me!
" In the second half of 2006 we look forward to the continued growth of product revenues and are confident that we will add significant licensing income from PSD502 to the top line.'

Timm Medical is bringing in great revenue going by the RNS and on top will be immediate licensing revenue from PSD502.

I am going to stick with next week as news week on deal news.
Good luck all!

News can still come November 2006 -still a few days to go -otherwise December 2006 it will defo come -company have stated this in the results RNS that PSD502 will bring in SIGNIFICANT licensing revenue in 2006 .

Honda, I too am hoping that news will soon be forthcoming, but predictions of when deals will be made can be very unreliable. I'm content to wait a while if necessary; happy to get in ahead of the herd.

soul -todays news is a start of more news -thats my take and PSD502 news this year 2006 will mean a great mark up so yes its best to get in before that happens.